Seth Ettenberg

Seth Ettenberg is the President and Chief Executive Officer of BlueRock Therapeutics, a biotechnology company focused on developing engineered cell therapies.12 Here are some key details about his background and role:

Career at BlueRock Therapeutics

Seth Ettenberg joined BlueRock Therapeutics as Chief Scientific Officer in 2020.2 He later became President and CEO, leading the company's efforts in developing regenerative medicines for various diseases.3 Under his leadership, BlueRock has been advancing its cell+gene platform to create engineered cellular medicines.1

Professional Background

Prior to BlueRock, Dr. Ettenberg had significant experience in the biotech industry:

• He was a founding member and Chief Scientific Officer at Unum Therapeutics, where he led teams that brought novel cellular therapies from invention to clinical testing.1
• He previously headed the Cambridge Site of Novartis' Oncology Biotherapeutics, overseeing drug development projects at Novartis Institutes for Biomedical Research (NIBR).1
• He also worked as a Project Leader and Senior Research Scientist at CuraGen.1

Expertise and Focus

Dr. Ettenberg is known for his expertise in:

• Engineered cell therapies
• Regenerative medicine
• Oncology drug development
• Building and leading high-performance research teams

At BlueRock, he oversees the company's research and discovery efforts, focusing on applying and expanding their cell+gene platform to create new cellular medicines.1

Education

Seth Ettenberg holds a Ph.D. in Molecular and Cell Biology from the Uniformed Services University.4

Personal Mission

Dr. Ettenberg is driven by a passion to bring meaningful therapies to patients, which he attributes to an "irrational obsession" to cure his brother's leukemia.4 This personal motivation influences his approach to drug development and team leadership at BlueRock Therapeutics.